Novo Nordisk AS v. Hims & Hers Health Inc

I. Executive Summary and Procedural Information

• Parties & Counsel:
  • Plaintiff: Novo Nordisk A/S (Denmark) and Novo Nordisk Inc. (Delaware)
  • Defendant: Hims & Hers Health, Inc. (Delaware) and Hims, Inc. (Delaware)
  • Plaintiff’s Counsel: Morris, Nichols, Arsht & Tunnell LLP; Covington & Burling LLP
• Case Identification: 1:26-cv-00143, D. Del., 02/09/2026
• Venue Allegations: Venue is alleged to be proper in the District of Delaware because Defendants are incorporated in Delaware and thus reside in the district.
• Core Dispute: Plaintiff alleges that Defendant’s compounded drug products infringe a patent covering the molecular structure of semaglutide, the active ingredient in Plaintiff's Ozempic® and Wegovy® medicines.
• Technical Context: The technology relates to glucagon-like peptide 1 (GLP-1) receptor agonists, a class of molecules that has become a cornerstone for treating type 2 diabetes and obesity.
• Key Procedural History: The complaint alleges that the patent-in-suit is listed in the FDA's Orange Book for Ozempic®, Wegovy®, and Rybelsus®. It also notes that on February 8, 2026, one day prior to filing suit, Plaintiff sent a letter to Defendants notifying them of their alleged infringement.

Case Timeline

II. Technology and Patent(s)-in-Suit Analysis

U.S. Patent No. 8,129,343 - Acylated GLP-1 Compounds

• Patent Identification: U.S. Patent No. 8,129,343, titled "Acylated GLP-1 Compounds," issued on March 6, 2012 Compl. ¶33 '343 Patent, cover

The Invention Explained

• Problem Addressed: The patent addresses the need for glucagon-like peptide 1 (GLP-1) compounds with a longer duration of action in vivo '343 Patent, col. 1:20-23 This is particularly important for patients with type 2 diabetes who may have a "substantial fear of injecting themselves" ("needle-phobia") and would benefit from a therapy requiring less frequent administration '343 Patent, col. 1:42-46
• The Patented Solution: The invention is a chemically modified GLP-1 analog. A key feature is the acylation of the peptide, specifically by attaching a lipophilic moiety to the lysine residue at position 26 '343 Patent, col. 2:58-61 This moiety, which contains at least two acidic groups, is designed to enable the compound to bind non-covalently to albumin in the bloodstream, thereby extending its half-life and protracting its therapeutic effect '343 Patent, abstract '343 Patent, col. 5:20-28
• Technical Importance: This approach created a "protracted GLP-1 compound" that could be administered less frequently than once daily, a significant clinical improvement over existing therapies at the time '343 Patent, col. 1:50-53

Key Claims at a Glance

• The complaint asserts independent claim 1 of the '343 Patent Compl. ¶¶64-66
• Independent claim 1, as corrected by a Certificate of Correction, recites:
  • A compound of the structure [chemical structure depicted]
  • where the amino acid sequence is that of SEQ ID NO:7.

III. The Accused Instrumentality

Product Identification

The accused products are Defendants' "Compounded GLP-1," "Compounded GLP-1 Microdose," and "Compounded GLP-1 Pill" Compl. ¶41

Functionality and Market Context

The Accused Products are compounded drugs that are marketed as containing semaglutide, the same active ingredient as in Plaintiff's FDA-approved drugs Ozempic® and Wegovy® Compl. ¶4 Compl. ¶48 The products are offered to consumers as weekly injectable solutions and a once-daily pill for weight management Compl. ¶48 The complaint alleges that Defendants market these products as lower-cost alternatives to the FDA-approved versions, with prices starting at $199 per month for injections and an introductory offer of $49 for the first month for pills Compl. ¶50 A screenshot provided in the complaint depicts a vial labeled "hims Compounded Semaglutide, 5 mg/2 mL" Compl. ¶49, Figure 3

IV. Analysis of Infringement Allegations

8,129,343 Patent Infringement Allegations

Identified Points of Contention

• Factual/Evidentiary Question: The central dispute appears to be one of chemical identity. What evidence will establish that the active pharmaceutical ingredient (API) in the Accused Products is the specific molecular structure recited in claim 1? The complaint rests its allegations on Defendants' own marketing claims, which may require confirmation through chemical analysis during discovery.
• Scope Question: While the claim is a composition of matter claim directed to a specific molecule, a potential issue could arise if the API in the Accused Products is a salt, ester, or other derivative of semaglutide that does not fall within the literal scope of the claimed structure.

V. Key Claim Terms for Construction

The complaint does not provide sufficient detail for analysis of key claim terms. The asserted independent claim recites a specific chemical structure, which generally limits the scope for claim construction disputes, as the structure itself defines the invention.

VI. Other Allegations

Indirect Infringement

The complaint alleges induced infringement under 35 U.S.C. § 271(b) Compl. ¶67 The factual basis for this allegation includes claims that Defendants provide instructions to providers and patients on how to use the Accused Products, thereby encouraging infringing acts Compl. ¶70 The complaint references a YouTube video titled "How to Take Compounded GLP-1 Injections" and a "step-by-step guide" on Defendants' website for injecting semaglutide as evidence of such instructions Compl. ¶¶59-60 A screenshot from the website shows a guide titled "How to Inject Semaglutide" Compl. ¶60, Figure 10

Willful Infringement

The complaint alleges willful infringement based on both pre- and post-suit knowledge of the '343 patent Compl. ¶73 Pre-suit knowledge is alleged based on Defendants' sophistication in the healthcare space, the '343 patent's listing in the FDA's Orange Book, and public statements by Defendants' CEO that allegedly demonstrate an awareness of the patent status of different GLP-1 drugs Compl. ¶39 Knowledge is also alleged based on a letter Plaintiff sent to Defendants on February 8, 2026, explicitly notifying them of the alleged infringement Compl. ¶¶40, 73

VII. Analyst’s Conclusion: Key Questions for the Case

This case appears to present a direct conflict over a specific chemical compound rather than a nuanced dispute over technological functionality. The primary questions for the court are likely to be:

• A core issue will be one of chemical identity: Can the plaintiff prove through discovery and chemical analysis that the active ingredient in the defendants' "Compounded GLP-1" products is, in fact, the precise molecular structure defined in claim 1 of the '343 patent? The case will likely hinge on the factual evidence establishing what compound is being sold.
• A key question for willfulness and potential enhanced damages will be one of scienter: What evidence demonstrates that the defendants knew or were willfully blind to the fact that their compounded product infringed the specific claims of the '343 patent, particularly in light of their CEO's public comments regarding the patent landscape for GLP-1 therapies?